Quarterly ResultMay 11, 2026, 04:32 PM
Cellectis Q1 Revenue $5.78M, Down 45.8%; Net Loss $(17.77)M
AI Summary
Cellectis S.A. reported a net loss of $(17.77) million for the three-month period ended March 31, 2026, a slight improvement from $(18.13) million in the prior year. Revenues decreased significantly by 45.8% to $5.78 million, primarily due to reduced collaboration activities under the AstraZeneca JRCA. Operating loss widened to $(25.17) million, driven by increased research and development expenses. However, a substantial increase in net financial gain helped mitigate the operating loss, and the company believes its cash and cash equivalents, along with fixed-term deposits, are sufficient to fund operations for at least twelve months.
Key Highlights
- Net loss for Q1 2026 was $(17.77) million, compared to $(18.13) million in Q1 2025.
- Revenues for Q1 2026 decreased by 45.8% to $5.78 million from $10.66 million in Q1 2025.
- Operating loss for Q1 2026 widened to $(25.17) million from $(14.18) million in Q1 2025.
- Research and development expenses increased by $5.3 million to $(27.19) million in Q1 2026.
- Selling, general and administrative expenses rose by $0.9 million to $(5.59) million in Q1 2026.
- Net financial gain was $7.45 million in Q1 2026, a significant improvement from a $(3.95) million loss in Q1 2025.
- Cash and cash equivalents stood at $34.84 million as of March 31, 2026.
- Total current assets were $204.55 million as of March 31, 2026, down from $236.24 million.